Form 8-K BIORA THERAPEUTICS, INC. For: Nov 21
- Wall Street ends higher, notches weekly gains as Fed meeting looms
- Intel pares losses but sheds $9 billion in value on dire outlook, dividend concerns
- Analysts rush to cut Intel (INTC) price targets following weaker than expected Q1 guidance
- Lucid Group (LCID) doubles on Saudi rumors
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
|(State or Other Jurisdiction
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant’s Telephone Number, Including Area Code:
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|Item 5.03.|| |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
Series X Preferred Stock
On November 21, 2022, Biora Therapeutics, Inc. (the “Company”) filed the Certificate of Designation of Series X Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, in connection with the preferred stock dividend previously disclosed on the Company’s Current Report on Form 8-K filed on November 10, 2022 (the “Dividend 8-K”). The description of the Series X Preferred Stock contained in the Dividend 8-K is incorporated herein by reference.
A copy of the Certificate of Designation is attached hereto as Exhibit 3.1 and is incorporated herein by reference.
Effective November 28, 2022, the board of directors of the Company adopted the Third Amended and Restated Bylaws of the Company (the “Bylaws”). The Bylaws, among other things, modify the quorum requirement such that the presence, in person or by proxy, of the holders of one-third of the voting power of the shares of capital stock issued and outstanding and entitled to vote (rather than the majority of the voting power of the stock outstanding and entitled to vote), including at least one-third of the outstanding shares of common stock, constitutes a quorum for the transaction of business at stockholder meetings.
The foregoing summary of the changes effected by the Bylaws does not purport to be complete and is qualified in its entirety by reference to the complete text of the Bylaws, which are attached hereto as Exhibit 3.2 and are incorporated herein by reference.
|Item 9.01.|| |
Financial Statements and Exhibits.
|3.1||Certificate of Designation for Series X Preferred Stock|
|3.2||Third Amended and Restated Bylaws of the Company|
|104||Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|Biora Therapeutics, Inc.|
|Date: November 28, 2022||By:|
|Eric d’Esparbes |
Chief Financial Officer
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- A Fusion of Sci-Fi and Heavy Industry Innovation, Flagship XCMG Machinery Equipment Features in Sci-Fi Blockbuster "The Wandering Earth II"
- LBank Exchange Will List MetaDoge (METADOGE) on January 30, 2023
- automotiveMastermind Integrates with DealerSocket to Improve Efficiency for Dealership Sales Teams
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!